Human SLPI ELISA Kit from R&D Systems
Rabbit Anti-Human OLFM1 Polyclonal Antibody, Unconjugated from Proteintech Group, Inc.
GELase 50X Reaction Buffer from EPICENTRE Biotechnologies
Axl, phospho ELISA development Kit, DuoSet IC Economy Pack from R&D Systems
Biology Products:(Date:12/2/2009)...re/ -- S*BIO Pte Ltd today announced data presenta... The American Society of Hematology 51st Annual Me...ll be presented on the clinical results from the P...ts safety, tolerability and pharmacokinetic/pharma...rom 100 to 600 mg. These doses were administered o...
(Date:12/2/2009)...Newswire-Asia/ -- Simcere Pharmaceutical Group,("S...g pharmaceutical company,specializing in the devel...neric and proprietary pharmaceuticals in China, to...uded in China,s National Drug Reimbursement List,(...uman Resources and Social,Security on November 30,...
(Date:12/2/2009)...re-Asia/ -- The world is going through,extraordina...s part of many,businesses and industries. It turns...immune to the economic downturn, because illness d...t of the difficult times this year, the pharmaceut...amp;D center in Shanghai, the largest of,its kind ...
(Date:12/2/2009)...e/ -- According to the National Institute of Healt... with diabetes already have some stage of diabetic... retina caused by leaky blood vessels, is a major ...one of the most feared diabetic complications. In... diabetes for 10 years or more will experience som...
Breaking Biology Technology:S*BIO Novel Oral JAK2 Inhibitor SB1518 Demonstrates Safety and Tolerability in Phase 1 Studies for the Treatment of Myeloproliferative and Other Hematological Disorders 2S*BIO Novel Oral JAK2 Inhibitor SB1518 Demonstrates Safety and Tolerability in Phase 1 Studies for the Treatment of Myeloproliferative and Other Hematological Disorders 3S*BIO Novel Oral JAK2 Inhibitor SB1518 Demonstrates Safety and Tolerability in Phase 1 Studies for the Treatment of Myeloproliferative and Other Hematological Disorders 4S*BIO Novel Oral JAK2 Inhibitor SB1518 Demonstrates Safety and Tolerability in Phase 1 Studies for the Treatment of Myeloproliferative and Other Hematological Disorders 5Simcere Announces 105 Drugs Included in China's National Drug Reimbursement List 2Simcere Announces 105 Drugs Included in China's National Drug Reimbursement List 3Pharma and Biotech Leaders to Converge in China at Asia Pharma R&D Leaders 2010 Summit 2Pharma and Biotech Leaders to Converge in China at Asia Pharma R&D Leaders 2010 Summit 3Study Shows Pine Bark Improves Microcirculation, Retinal Swelling And Visual Acuity In Early Diabetic Retinopathy 2Study Shows Pine Bark Improves Microcirculation, Retinal Swelling And Visual Acuity In Early Diabetic Retinopathy 3Study Shows Pine Bark Improves Microcirculation, Retinal Swelling And Visual Acuity In Early Diabetic Retinopathy 4